Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index in terms of anti-tumour efficacy and cardiovascula...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Claire M. Patterson, Srividya B. Balachander, Iain Grant, Petar Pop-Damkov, Brian Kelly, William McCoull, Jeremy Parker, Michael Giannis, Kathryn J. Hill, Francis D. Gibbons, Edward J. Hennessy, Paul Kemmitt, Alexander R. Harmer, Sonya Gales, Stuart Purbrick, Sean Redmond, Matthew Skinner, Lorraine Graham, J. Paul Secrist, Alwin G. Schuller, Shenghua Wen, Ammar Adam, Corinne Reimer, Justin Cidado, Martin Wild, Eric Gangl, Stephen E. Fawell, Jamal Saeh, Barry R. Davies, David J. Owen, Marianne B. Ashford
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Biology (General)
QH301-705.5
Accès en ligne:https://doaj.org/article/722de1f4d6464ec9a94bce51fe4fc356
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/722de1f4d6464ec9a94bce51fe4fc356

Documents similaires